Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 131 followers
Latest posts
Last updated 3 days ago
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
3 days ago
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy...
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
4 days ago
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD)...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
7 days ago
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress...
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
11 days ago
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney...
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
11 days ago
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained...
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
14 days ago
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile...
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
14 days ago
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
15 days ago
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate...
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond
20 days ago
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond halesmi2 Tue...
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
20 days ago
New Novartis data at ERA 2026 advance scientific understanding of kidney disease...
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
25 days ago
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer...
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
28 days ago
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto®...